To figure out market landscape, brand awareness, latest trends, possible future issues, industry trends and customer behaviour, the finest market research report is very essential. A persuasive Clinical Oncology Next Generation Sequencing Market research report provides major statistics on the market status of global and regional manufacturers and is a helpful source of assistance and direction for companies and individuals interested in the Healthcare industry. Clinical Oncology Next Generation Sequencing market study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors.
Competitive analysis studied in the finest Clinical Oncology Next Generation Sequencing market report assists to get ideas about the strategies of key players in the market. Under market segmentation, research and analysis is done based on application, vertical, deployment model, end user, and geography. The key research methodology used here by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Clinical Oncology Next Generation Sequencing market research document gives information about company profile, product specifications, capacity, production value, and market shares for each company for the year 2022 to 2029 under the competitive analysis study.
According to the American Cancer Society, 1.7 million additional cancer cases and 0.6 million cancer deaths occurred in the United States in 2019. Lung, prostate, bladder, and female breast cancer are the four most common cancers worldwide, accounting for 43% of all new cancer cases. As a result, demand for clinical oncology next-generation sequencing is predicted to rise as cancer incidence rates rise globally. Clinical oncology next-generation sequencing companies are increasingly investing in workflow automation to improve accuracy and lower sample-to-sample variability.
Data Bridge Market Research analyses that the clinical oncology next generation sequencing market which was USD 592.56 million in 2021, would rocket up to USD 1825.30 million by 2029, and is expected to undergo a CAGR of 15.1% during the forecast period 2022 to 2029.
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
This clinical oncology next generation sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the clinical oncology next generation sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Download PDF Sample of Global Clinical Oncology Next Generation Sequencing Market Research Report: - https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-clinical-oncology-next-generation-sequencing-market
Next-generation sequencing is a DNA or RNA technique that permits several reactions to be carried out simultaneously. This is one of the most important applications of next-generation sequencing in oncology. In recent years, NGS has changed cancer genetics by providing researchers greater access to genomic and transcriptome data. Next-generation tumour and germline DNA sequencing is used in oncology screening for therapeutic application.
Some of the major players operating in the clinical oncology next generation sequencing market are:
- Illumina, Inc. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Hoffmann-La Roche Ltd. (Switzerland)
- Agilent Technologies Inc. (U.S.)
- Myriad Genetics Inc. (U.S.)
- BGI (China)
- Perkin Elmer Inc. (U.S.)
- Foundation Medicine Inc. (U.S.)
- PacBio (U.S.)
- Oxford Nanopore Technologies plc. (U.K.)
- Paradigm Diagnostics Inc. (U.S.)
- Caris Life Sciences (Japan)
- Partek, Incorporated (U.S.)
- Eurofins Scientific (Luxembourg)
- Qiagen (Germany)
Clinical Oncology Next Generation Sequencing Market Dynamics
Drivers
- Increase in cancer cases
The clinical oncology next-generation sequencing market is projected to be significantly impacted by personalized medicine and oncology improvements. Rising cancer prevalence, high acceptance of sequencing-based diagnostics platforms among practicing oncologists, decrease in the cost of genetic sequencing, and increased government R&D funding are some of the reasons expected to boost market growth. On the other hand, high adoption of this technique over single-gene testing and higher adoption of clinical oncology next-generation sequencing technology and platforms in academia projects will fuel a slew of new opportunities, propelling the clinical oncology next generation sequencing market forward from 2022 to 2029.
- New technological Innovatives
According to the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), cancer was the top cause of death worldwide in 2020, with over 10 million fatalities. In addition, 19.3 million additional cases were reported globally. New creative technologies, such as next generation sequencing, are being used to address this worldwide burden and lower mortality rates. As a result, the clinical oncology next generation market is growing at a faster rate.
- Reduction in the cost of NGS platforms
The factor aiding the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing approaches provide a high percentage of reads as well as low cost per read. Leading players are introducing low-cost sequencing approaches. Similarly, the worldwide clinical oncology next generation sequencing market will expand over the forecast period as more people use next generation sequencing for liquid biopsy.
View Detailed Global Clinical Oncology Next Generation Sequencing Market @ https://www.databridgemarketresearch.com/reports/global-clinical-oncology-next-generation-sequencing-market
Global Clinical Oncology Next Generation Sequencing Market Scope
The clinical oncology next generation sequencing market is segmented on the basis of technology, workflow, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Technology
- Whole Genome Sequencing
- Whole Exome Sequencing
- Targeted Sequencing and Resequencing Centrifuges
Workflow
- Pre-Sequencing
- Sequencing
- Data Analysis
Application
- Screening
- Sporadic Cancer
- Inherited Cancer
- Companion Diagnostics
- Other Diagnostics
End-user
- Hospitals
- Clinics
- Laboratories
View Detailed Table of Content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-clinical-oncology-next-generation-sequencing-market
The research examines the characteristics of the target market, as well as recent developments and patterns, industry opportunities, growth rates, sector expansion strategies, and emerging technologies. The Clinical Oncology Next Generation Sequencing market research report offered a very useful resource that can help stakeholders, manufacturers, decision-makers, and market participants to become familiar with all the factors impacting the growth of the global market. The report includes SWOT, and market analyses to provide a deep and clear understanding of aspects of the Clinical Oncology Next Generation Sequencing market.
Browse More Reports
https://www.databridgemarketresearch.com/reports/europe-ophthalmology-market
https://www.databridgemarketresearch.com/reports/asia-pacific-ophthalmology-market
https://www.databridgemarketresearch.com/reports/middle-east-and-africa-ophthalmology-market
https://www.databridgemarketresearch.com/reports/north-america-ophthalmology-market
About Data Bridge Market Research, Private Ltd
Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.
Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. “Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.”
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
